Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sage Drug Could Help Take Stigma Out Of Postpartum Depression

Executive Summary

SAGE Therapeutics Inc. could offer the one in eight new mothers suffering from postpartum depression (PPD) freedom from the overwhelming condition with the first-ever drug to specifically treat PPD if the rapid and durable response to SAGE-547 in a small Phase II clinical trial holds up in future studies.

You may also be interested in...

All Smiles At Sage As Phase III Postpartum Depression Data Are Positive

The company plans to file an NDA with FDA in the first half of 2018 for an intravenous formulation of brexanolone, which could be the first treatment specifically for postpartum depression.

Sage Therapeutics on PRIME, Partnerships and Pricing For Its PPD First

Sage Therapeutics is on track to deliver the first ever drug to be indicated for postpartum depression. The company discusses plans for launch and whether or not it wants to partner.

VC Roundup: October Brings Several New Venture Funds, Including Third Rock’s Fourth

Third Rock closed a $616m venture capital fund, exceeding the firm’s goal of $600m to fund newly formed biopharma companies, following Sofinnova and others with new VC and debt funds for early- to mid-stage life science companies. Also, five drug developers raised $256m in new VC cash.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts